Schuylkill Chamber of Commerce receives Voice for Children Award
The chamber received the PennSEYC Voice for Children Award at the organization's annual gala in Hershey Lodge.
It is the only statewide award in Pennsylvania that recognizes the work of grassroots leaders on behalf of early childhood education.
Jen DeBall, PennSEYC executive director, recognized the key role child care plays in child development, the ability to allow parents to work and the overall economy.
'These steps forward would not have been possible without the critical role champions have played in advocating for high-quality early care and educational settings,' she said. 'We are excited to celebrate the Schuylkill Chamber and all those who are part of the early childhood profession.'
Robert S. Carl Jr., chamber president and CEO, and Samantha M. Chivinski, executive vice president, accepted the award.
'The award is special as we continue our across-the-commonwealth advocacy for child care teacher recruitment and retention,' Carl said, 'encouraged by the $55 million allocated in the state budget by Gov. Josh Shapiro.'
The chamber is committed to preserving the appropriation through the legislative budget process as an important first step in an ongoing advocacy to bolster child care in the state.
'We are proud to lead a growing coalition of chambers of commerce and economic development organizations across the state who understand the priority of child care,' Carl added.
Steve Doster, ReadyNation state director, noted the Schuylkill chamber's role in marshalling chambers to work for a solution to the teacher shortage in child care centers.
'Samantha and Bob do this work,' he said, 'because they see first-hand how child care teachers are the workforce behind the workforce.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Swiss knife maker considers production shift to ease U.S. tariffs
BERLIN (Reuters) -Victorinox, maker of Swiss army knives, is considering moving part of its production to the United States to lessen the impact of import tariffs on its business, the company's CEO told the Wirtschaftswoche business magazine. "We are looking into carrying out directly on site individual processing steps at the end of the value chain, such as the final cleaning and packaging of commercial knives," Carl Elsener said in an interview published on Tuesday. "That would reduce the value of the goods on which we have to pay customs duty by 10% to 15%," he added. Switzerland has been particularly hard hit by Washington's trade policy under President Donald Trump, who earlier this month ratcheted up U.S. tariffs on Swiss imports to 39%. The U.S. is an important market for Swiss machinery, watches and chocolate. Victorinox, which makes commercial knives as well as its well-known pocket knives, generates some 13% of its revenue in the country. Elsener told WirtschaftsWoche the customs duties were coming at an already difficult time. "The strong Swiss franc has put our competitiveness and our margins under considerable pressure," he told the magazine. However, he added that high inventories in the U.S. ensured that the tariffs would not affect Victorinox until the beginning of next year. (Writing by Rachel MoreEditing by Madeline Chambers) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage
Carlsmed Inc. (NASDAQ:CARL), an AI-powered innovator in spine surgery, is poised for significant growth following key advancements and strong analyst projections. The company recently secured additional Medicare reimbursement for its aprevo personalized interbody implants for cervical fusion procedures, effective October 1, enhancing its financial outlook. This favorable reimbursement, granted through the Centers for Medicare & Medicaid Services' (CMS) New Technology Add-On Payment (NTAP) program in the Hospital Inpatient Prospective Payment Systems (IPPS) Final Rule for fiscal year 2026, means cervical fusion procedures using aprevo devices will be eligible for an additional $21,125 beyond standard Medicare Severity-Diagnosis-Related Groups (MS-DRGs) for qualifying inpatient benefit extends to private payors as well, utilizing unique ICD-10-PCS procedure codes. Carlsmed, which priced its initial public offering of 6.7 million shares at $15 per share in July, focuses on AI-enabled personalized spine surgery solutions. Its aprevo cervical system, having received FDA Breakthrough Device designation, is anticipated for a U.S. commercial launch in of America Securities (BofA) has initiated coverage on Carlsmed with a Buy rating and a price forecast of $16, recognizing the company's potential to establish a new standard of care in spine fusion. BofA analyst Travis Steed highlighted Carlsmed's differentiated technology and robust outlook, assigning a premium valuation of 5x 2026 estimated revenue. This premium, higher than recent medtech IPOs and other spine companies, is justified by Carlsmed's projected high revenue growth and strong gross margin profile. BofA conservatively forecasts Carlsmed will add around 20-25 new surgeons each quarter through 2027, indicating a steady increase in adoption. Carlsmed forecasts impressive top-line growth: 66% in 2025 and an annual 40-45% through 2028. Its asset-light business model is expected to support profitability, with gross margins in the mid-70s and capital expenditures at just 1% of sales, significantly lower than the approximately 10% for traditional spine peers. BofA estimates the total spine market at roughly $1.4 billion, with a compound annual growth rate (CAGR) of approximately 1.5%. In the first quarter of 2025, the global spine market (including biologics) saw 2.6% organic growth, driven by a 4.1% increase in the U.S. market. Despite the market being largely commoditized and dominated by major players like Medtronic Plc (NYSE:MDT), Globus Medical Inc (NYSE:GMED), Alphatec Holdings Inc. (NASDAQ:ATEC), Johnson and Johnson (NYSE:JNJ), and Orthofix Medical Inc. (NYSE:OFIX) (who collectively hold about 70% of the market), spine surgeons notably favor new technology. The remaining 30% of the market is split among many smaller companies, creating an opportunity for new market entrants with disruptive technology like Carlsmed's to gain traction. BofA sees significant market share capture potential for Carlsmed, with analyst Steed estimating total revenue of $133 million in 2028, representing only about 1% of the total U.S. spine market. Price Action: CARL stock is trading higher by 0.88% to $13.70 at last check Monday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
5 days ago
- Yahoo
Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
LAVAL, QC / / August 15, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced that Paulson Capital Inc. and certain affiliates and managed funds have increased their ownership of the Company's common shares. The increase reflects the acquisition by Paulson Capital Inc. and certain affiliates and managed funds of the net long position of 34,721,118 common shares previously held by Mr. Carl C. Icahn and his affiliates (collectively, "Icahn Group"). The Company is not a party to any agreement or arrangement with Paulson Capital Inc. or its affiliates or the Icahn Group in connection with these transactions. Based on information provided to the Company, Paulson Capital Inc. and certain affiliates and managed funds beneficially owns approximately 19.13% of the Company's outstanding common shares as of the date hereof. The Company further announced that the Director Appointment and Nomination Agreement, dated as of February 23, 2021, between the Company and Icahn Group, terminated pursuant to its terms when the Icahn Group's net long position in the Company's shares fell below the specified threshold. In connection with the termination, Brett M. Icahn and Steven D. Miller have resigned from the Board of Directors (the "Board"). "I believe there is significant value in Bausch Health and am confident in the Company's efforts to maximize shareholder value. I am excited about the underlying business prospects in both Bausch Health and its subsidiary, Bausch + Lomb Corporation," John A. Paulson, Chairperson of the Bausch Health Board, said. "I also want to thank Brett and Steven for their dedication and valuable contributions to the Company." About Bausch Health Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit and connect with us on LinkedIn. Forward-looking Statements This news release may contain forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. Investor Contact: Media Contact: Garen Sarafian Katie Savastano ir@ (877) 281-6642 (toll free) (908) 569-3692 SOURCE: Bausch Health Companies Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
